The Fly | ASPI

ASP Isotopes, Inc.

· ASPI

Dashboard

Financials

Ratios

Transcripts

Valuation

Over a week ago

Largest borrow rate increases among liquid names

May 28, 8:45 AM

What You Missed On Wall Street On Tuesday

+26

May 26, 4:21 PM

Midday Fly: Eli Lilly to acquire vaccine makers, BP chair removed

+24

May 26, 11:59 AM

Unusually active option classes on open May 26th

May 26, 9:40 AM

ASP Isotopes restarted first 18 stages of Silicon-28 facility

ASPI

May 26, 8:30 AM

Largest borrow rate increases among liquid names

May 18, 8:45 AM

ASP Isotopes Inc options imply 7.5% move in share price post-earnings

ASPI

May 15, 1:19 PM

ASP Isotopes subsidiary enters into agreement for nuclear fuel supply

ASPI

May 11, 9:19 AM

ASP Isotopes Inc call volume above normal and directionally bullish

ASPI

Apr 23, 11:45 AM

Largest borrow rate increases among liquid names

Apr 7, 8:45 AM

ASP Isotopes Inc options imply 6.4% move in share price post-earnings

ASPI

Mar 31, 2:19 PM

ASP Isotopes Inc options imply 9.9% move in share price post-earnings

ASPI

Mar 30, 1:34 PM

ASP Isotopes announces pact between Quantum Leap Energy, University of Bristol

ASPI

Mar 24, 7:50 AM

What You Missed On Wall Street On Friday

+31

Mar 6, 4:05 PM

Midday Fly By: Rising oil prices, falling employment sink stocks

+30

Mar 6, 12:06 PM

ASP Isotopes Inc call volume above normal and directionally bullish

ASPI

Mar 6, 12:05 PM

ASP Isotopes announces Quantum Leap enters MOU with U.S. energy company

ASPI

Mar 6, 7:33 AM

ASP Isotopes' Quantum Leap appoints Nate Salpeter as CTO

ASPI

Mar 5, 7:38 AM

ASP Isotopes Inc call volume above normal and directionally bullish

ASPI

Feb 25, 2:45 PM

ASP Isotopes announces Quantum Leap, Necsa advance collaboration

ASPI

Feb 23, 7:34 AM

ASP Isotopes establishes Quantum Leap Energy Strategic Advisory Board

ASPI

Feb 19, 8:46 AM

ASP Isotopes announces QLE to establish global headquarters in Texas

ASPI

Feb 17, 7:46 AM

ASP Isotopes provides production update on Renergen Helium Project

ASPI

Jan 29, 7:37 AM

Unusually active option classes on open January 9th

Jan 9, 9:40 AM

ASP Isotopes closes acquisition of Renergen

ASPI

Jan 7, 8:36 AM

Proprietary PCIS Technology: Their Photo-Chemical Isotope Separation (PCIS) method offers a unique, potentially lower-cost and more energy-efficient alternative to traditional isotope production methods, providing a distinct technological edge.

Cost-Effective Production Potential: The PCIS process is designed to significantly reduce the capital and operational expenses associated with isotope manufacturing, enabling more competitive pricing and higher margins.

Highly Scalable Manufacturing: The modular nature of the PCIS technology allows for rapid and efficient scaling of production capacity to meet increasing market demand across various isotope applications.

Technology Development and Commercialization Risks: The company's proprietary isotope enrichment technology may not achieve commercial scale, cost-effectiveness, or desired purity, potentially delaying or preventing product launch.

Significant Capital Requirements and Funding Risks: Developing and operating isotope production facilities are highly capital-intensive, requiring substantial ongoing financing that may not be available on favorable terms or at all.

Intense Competition and Market Adoption Risks: The isotope market is competitive, and ASPI may struggle to differentiate its products, achieve market acceptance, or compete effectively against established or new entrants.